Santen, Tracon discontinue development of wet AMD treatment

Issue: March 2020

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Santen and Tracon Pharmaceuticals have discontinued development of DE-122, their wet age-related macular degeneration treatment candidate, following data analysis of a phase 2a study, the companies announced in a press release.

The randomized, controlled AVANTE clinical study evaluated visual acuity in wet AMD patients who had received six monthly DE-122 treatments with Lucentis (ranibizumab, Genentech) or Lucentis alone. Topline data found no improvement in visual acuity when DE-122 was added to Lucentis.

Santen licensed the development rights to DE-122 from Tracon in 2014. The discontinuation of its development is not expected to have a material impact on Santen’s fiscal year financial results, the release said.